A U.S. biotech company’s experimental oral therapy, neflamapimod, designed to treat age-related brain disorders, has been selected for inclusion in the EXPERTS-ALS platform study, a U.K. initiative aiming to rapidly test potential treatments for amyotrophic lateral sclerosis (ALS). Developer Cervomed announced in a company press release that its treatment…